Bioactive compound nanoparticles for Alzheimer's disease.

Area of Science:

• Neuroscience
• Biomedical Engineering
• Pharmacology

Background:

• Alzheimer's disease (AD) is a major cause of dementia, characterized by amyloid plaques and neurofibrillary tangles.
• Current treatments manage symptoms but do not alter disease progression.
• The blood-brain barrier (BBB) limits the efficacy of conventional therapies.

Purpose of the Study:

• To explore the potential of bioactive nanoparticles for Alzheimer's disease treatment.
• To investigate how nanoparticles can overcome the blood-brain barrier.
• To review nanoparticle systems targeting AD pathologies.

Main Methods:

• Review of existing literature on nanoparticle delivery systems for AD.
• Analysis of mechanisms for crossing the blood-brain barrier (e.g., transcytosis, cell-mediated transport).
• Evaluation of bioactive components with anti-inflammatory and antioxidant properties.

Main Results:

• Bioactive nanoparticles can target amyloid aggregation and tau hyperphosphorylation.
• Various nanoparticle systems demonstrate BBB crossing capabilities in disease models.
• Nanoparticles offer advantages over traditional drug delivery for AD.

Conclusions:

• Bioactive nanoparticles show promise for treating Alzheimer's disease by addressing core pathologies and improving drug delivery.
• Challenges include toxicity, bioavailability, and regulatory hurdles.
• Further research and development are warranted for clinical application.